A Formulation Scientist's Guide to Omega-3 Supplements

Walk into any pharmacy and you'll see hundreds of omega-3 supplements. The labels promise cardiovascular health, brain function, joint support, and inflammation reduction. The bottles say "1000mg." The prices range from $10 to $60.

Most of them are garbage.

The clinical evidence for omega-3s is overwhelming. But the products on shelves bear almost no resemblance to what's actually been studied in research. They're underdosed by a factor of ten. They use inferior molecular forms with poor bioavailability. Over half fail basic quality tests for oxidation. And the labeling is deliberately misleading.

As formulation scientists, we spend our days reverse-engineering successful clinical trials and translating them into manufacturable products. When we look at the omega-3 market, we see a systematic failure: brands racing to the bottom on price while consumers unknowingly take rancid, underdosed supplements that can't possibly deliver the benefits they're paying for.

This guide will show you exactly what clinical science says about omega-3 supplementation, and why most products fall catastrophically short.

There are three primary omega-3 fatty acids, and they're not interchangeable.

Alpha-Linolenic Acid (ALA) is the plant-based omega-3 found in flaxseeds, chia seeds, walnuts, and hemp. Your body cannot produce ALA, so it's technically essential. But here's the problem: ALA isn't the form your body actually needs.

Eicosapentaenoic Acid (EPA) is a 20-carbon long-chain omega-3 found primarily in marine sources. EPA is the anti-inflammatory powerhouse. It drives cardiovascular benefits, modulates immune response, and shows up in depression trials.

Docosahexaenoic Acid (DHA) is a 22-carbon fatty acid that comprises the structural foundation of brain tissue, retinal cells, and cell membranes throughout the body. It builds developing brains in fetuses and maintains cognitive function in adults.

The ALA Conversion Problem

The supplement industry loves to sell you on plant-based omega-3s. The pitch is simple: get your omega-3s from flax oil or chia seeds, skip the fish, save the oceans.

The problem is conversion efficiency. Your body can theoretically convert ALA into EPA and DHA, but the process is astonishingly inefficient:

• ALA → EPA:: 5-10% conversion
• ALA → DHA:: 2-5% conversion (some studies show as low as 2-3.8%)

Why is it so limited? Because the conversion pathway depends on Δ6-desaturase and elongase enzymes that are already overwhelmed with other metabolic processes. A diet high in saturated fat further suppresses conversion. Genetic variation, hormonal status, and overall dietary context all conspire to make this pathway essentially non-functional for therapeutic purposes.

Eating flax seeds will not give you meaningful levels of EPA or DHA. If you want the cardiovascular, cognitive, and anti-inflammatory benefits documented in thousands of studies, you need direct supplementation from marine or algal sources. Period.

Once you've accepted that you need EPA and DHA from marine sources, the next question is: what molecular form?

The industry gets messy here, and formulation scientists earn their keep.

The Four Major Forms

Natural Triglyceride (TG) is the form found in whole fish. Three fatty acid chains attached to a glycerol backbone. Maximum concentration: about 30% EPA+DHA. That's it. The rest is neutral fat.

Ethyl Ester (EE) is what happens when you molecularly distill fish oil to concentrate it. During processing, the fatty acids are detached from glycerol and re-attached to ethanol molecules. This allows concentrations up to 90% EPA+DHA. It's synthetic, but it's also how most prescription formulations (Lovaza, Omtryg) are made.

Re-esterified Triglyceride (rTG) takes ethyl esters and converts them back to triglyceride form. You get the high concentration of EE (60-90% EPA+DHA) combined with the natural molecular structure of TG. Best of both worlds, in theory. The caveat: only 55-60% may be true rTG in some products. The fidelity of re-esterification varies by manufacturer.

Phospholipid (PL) is what you get from krill oil. EPA and DHA are attached to phosphatidylcholine instead of glycerol. Because phospholipids are what cell membranes are made of, the theoretical advantage is easier passage through the intestinal wall.

Short-Term Absorption: rTG Wins

In acute bioavailability studies, rTG shows roughly 70% better absorption than EE forms when taken in a fasted state. Natural TG forms show about 124% relative bioavailability compared to 73% for EE.

The mechanism: your pancreatic lipase has to cleave the ethyl group from EE before it can be absorbed, and that process is 10-50 times slower than for natural triglycerides. Since free EPA and DHA ethyl esters don't appear in blood after cleavage, movement into circulation may be limited by the availability of glycerol molecules needed to resynthesize triglycerides for transport.

Long-Term Reality: The Gap Narrows

Here's where it gets interesting. Long-term steady-state studies show that when fish oil is routinely supplemented over weeks or months, the absorption differences between EE and rTG largely disappear. Both forms are effective at raising omega-3 levels in the body over extended periods.

Translation: if you take your omega-3 supplement every day with food, the molecular form matters less than you think. Meal-dependent absorption improves dramatically for all forms. When taken with a fatty meal, the differences between forms become less pronounced. The more important variables are total dose, concentration level, and quality (oxidation status).

Krill Oil: The Phospholipid Advantage

Krill oil deserves special mention because 30-65% of its fatty acids are incorporated into phospholipids rather than triglycerides. Multiple studies show superior absorption under 2,000mg doses compared to fish oil.

One study found that krill oil supplementation at 2g/day resulted in equal DHA bioavailability and increased EPA bioavailability compared to 4g/day of fish oil. Literally half the dose. The phospholipid structure facilitates passage through intestinal cell membranes more efficiently.

Krill also contains endogenous astaxanthin (the red pigment), which provides natural antioxidant protection against oxidation. The catch? Krill oil is more expensive and provides lower absolute amounts of EPA+DHA per capsule.

Algal Oil: The Vegan Solution

Algal oil extracted from microalgae species like Crypthecodinium cohnii and Schizochytrium sp. provides a vegan DHA source with bioavailability comparable to well-formulated fish oil. Studies show dose-dependent increases in blood DHA levels from 200-1000mg/day after four weeks.

The sustainability benefits are real: algae are the original producers of omega-3s (fish accumulate them by eating algae-consuming organisms), cultivation occurs in controlled conditions, and there's no risk of heavy metal contamination or contribution to overfishing.

For most applications, rTG form at 60-90% concentration provides the best balance of bioavailability, cost, and clinical dosing feasibility. But the form obsession is overblown. Dose and quality matter more.

The supplement industry loves to lump EPA and DHA together as "omega-3s" and call it a day. But these molecules have distinct biological roles, and the clinical evidence increasingly suggests that ratios matter.

EPA: The Anti-Inflammatory

EPA's primary mechanism is inflammation modulation. It inhibits leukocyte chemotaxis, suppresses adhesion molecule expression, and reduces production of inflammatory cytokines (IL-1β, TNF-α) and pro-inflammatory prostaglandins.

EPA gets metabolized into specialized pro-resolving mediators (SPMs) that actively resolve inflammatory cascades. In rodent models of chronic stress, intracranial injection of these mediators inhibits astrocyte and microglia activation in the hippocampus and reduces synaptic degradation.

The REDUCE-IT trial is the most successful omega-3 cardiovascular trial to date. It enrolled 8,179 statin-treated patients with elevated triglycerides and used 4g daily of pure EPA (icosapent ethyl). Result: 25% reduction in cardiovascular events. Among patients who'd had a recent acute coronary syndrome, the reduction was even larger: 37%.

The Japan EPA Lipid Intervention Study (JELIS) enrolled 18,645 patients with high cholesterol and showed 19% reduction in major coronary events with 1,800mg EPA added to statin therapy. The benefit was independent of cholesterol reduction, both groups lowered LDL similarly. This suggests EPA works through mechanisms beyond lipid modification.

For depression, twelve studies with 498 combined participants reported encouraging outcomes with EPA-predominant formulations specifically in treatment-resistant depression. The critical moderator: systemic inflammation. Patients with hs-CRP ≥1 mg/L showed significantly greater improvement on depression rating scales. EPA also improved fatigue and sleep difficulties in patients with inflamed depression. EPA appears to work for "inflamed depression," not depression in general.

DHA: The Structural Component

DHA is fundamentally different. It's the primary structural component of brain tissue, literally what your neurons are built from. It's critical for fetal brain development, retinal function, and maintaining cognitive performance across the lifespan.

Prenatal and infant development: Women randomized to 600mg/day DHA during the last two trimesters showed benefits on infant visual habituation at 4, 6, and 9 months. Large RCTs found fewer early preterm births among women with low baseline DHA status assigned to 800mg DHA daily. Since preterm birth is a well-established predictor of suboptimal cognitive outcomes, the implications are significant.

Adult cognitive health: DHA supplementation in randomized controlled trials shows benefit on cognitive decline in individuals with mild cognitive impairment (though no benefit in Alzheimer's disease). In cognitively healthy individuals with coronary artery disease, 3.36g EPA+DHA daily slowed cognitive aging by 2.5 years.

Combined EPA+DHA: Cardiovascular Mechanisms

For general cardiovascular health, both EPA and DHA contribute through multiple mechanisms: lipid metabolism modulation, inflammation reduction, platelet and endothelial function improvement, gut-heart axis regulation, ion channel effects, and autonomic function via vagal tone.

Cohort data and meta-analyses consistently link higher intake or circulating levels of EPA and DHA to reduced cardiovascular event risk.

Important dose-response finding: Protective effect against atrial fibrillation when EPA and DHA consumed in moderate amounts (up to ~750mg/day), but high-dose supplementation may increase atrial fibrillation risk. This showed up in the STRENGTH trial, which was terminated early partly due to increased new-onset atrial fibrillation (2.2% omega-3 group vs 1.3% placebo).

The Pattern from Clinical Trials

REDUCE-IT (4g pure EPA): Massive success. 25% reduction in cardiovascular events.

JELIS (1,800mg EPA): 19% reduction in coronary events.

VITAL (EPA+DHA combined): Did not reduce primary composite endpoint, but showed 28% reduction in total MI, 17% reduced risk for total coronary heart disease, and 50% reduction in fatal MI on secondary analysis.

ASCEND (EPA+DHA in diabetic patients): Did not reduce primary composite outcome of serious vascular events, but exploratory analysis showed 19% relative risk reduction in vascular deaths (achieved statistical significance).

STRENGTH (EPA+DHA combined): Terminated early for futility.

The pattern suggests EPA monotherapy may be more effective than combined formulations for cardiovascular applications, though the reasons aren't entirely clear.

Match the EPA:DHA ratio to the clinical indication.

• EPA-dominant (2:1 or higher):: Cardiovascular disease, inflammation, mood disorders
• DHA-dominant (1:2 or higher):: Cognitive function, prenatal health, brain development
• Balanced (3:2):: General wellness when no specific therapeutic target exists

There are six prescription omega-3 products approved by the FDA in the United States. Every single one of them delivers 3-4 grams of EPA+DHA daily. Not 300mg. Not 1,000mg. Three to four grams.

Vascepa (icosapent ethyl) contains 876mg EPA per 1,000mg capsule. The prescribed dose is 4 grams daily, providing 3.5g of EPA. It's an EPA-only formulation in ethyl ester form. This is what was used in the REDUCE-IT trial. Vascepa is uniquely approved not just for severe hypertriglyceridemia (≥500 mg/dL), but also for cardiovascular risk reduction in statin-treated patients with triglycerides ≥150 mg/dL.

Lovaza (omega-3-acid ethyl esters) contains 465mg EPA and 375mg DHA per 1-g capsule. The prescribed dose is 4 grams daily, providing 3.1g EPA+DHA. Ethyl ester form.

Omtryg is a generic version of similar composition, delivered in 1.2-g capsules. Ethyl ester form.

Epanova (omega-3-carboxylic acids) contains 550mg EPA and 200mg DHA per 1-g capsule, providing 3g EPA+DHA per 4-g dose. Free fatty acid (carboxylic acid) form. This was used in the STRENGTH trial, which was terminated early for futility.

All products are FDA-approved as adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (TG levels ≥500 mg/dL). The dose: 4 grams daily, taken either in a single dose or two 2-gram doses.

The fact that every FDA-approved omega-3 product delivers 3-4g daily is not a coincidence. That's the dose required to produce measurable clinical effects. The FDA doesn't approve homeopathic doses. If 300mg worked, prescription omega-3s would be 300mg.

The over-the-counter market exists in a completely different reality. Most retail products deliver 300mg per capsule and make vague "supports heart health" claims that can't be substantiated at the dose provided. Consumers take one capsule daily, thinking they're getting cardiovascular benefits, when they're actually getting less than 10% of the effective dose.

Clinical trials that demonstrate meaningful health benefits use 2-4 grams of EPA+DHA daily. Sometimes more.

The typical retail omega-3 supplement delivers 300mg per capsule.

Do the math. That's a factor of ten gap between clinical evidence and consumer products.

Effective Doses by Indication

Cardiovascular risk reduction (general prevention): ~1g EPA+DHA daily. This is the dose that shows 20-30% reduction in cardiovascular mortality in large secondary prevention trials.

High triglycerides (therapeutic): 3-4g EPA+DHA daily. The FDA-approved prescription dose for severe hypertriglyceridemia is 4g daily. At this dose, clinical trials report triglyceride reductions ≥30%.

Anti-inflammatory effects: At least 2g EPA+DHA daily. Some evidence suggests 2-3g is necessary for therapeutic anti-inflammatory benefits. Higher doses (>3g/day) reliably reduce triglyceride concentrations. Interestingly, one study in healthy adults with moderate hypertriglyceridemia found that neither 0.85g/day nor 3.4g/day improved endothelial function or inflammatory markers over 8 weeks. This suggests inflammatory benefits may be condition-specific or require longer duration than acute metabolic studies capture.

Cognitive health and brain function: 1-2g DHA for cognitive support. For mild cognitive impairment, omega-3s may improve attention, processing speed, and immediate recall. Prenatal supplementation requires 600-800mg DHA daily.

Depression and mood disorders: 2-3g EPA for depression with elevated inflammatory markers (hs-CRP ≥1 mg/L). EPA shows higher efficacy specifically in inflamed depression.

Raising Omega-3 Index to cardioprotective levels (≥8%): Generally requires >1,000mg EPA+DHA for 12 weeks or longer. Practical recommendations: 1,000-1,500mg daily.

What Most Products Actually Deliver

Natural fish oil contains a maximum of 30% EPA+DHA combined. The rest is neutral fat and other fatty acids.

That means a 1,000mg fish oil capsule delivers only 300mg of actual omega-3s.

Look at the supplement facts panel, not the front label. The "1000mg" prominently displayed on the front refers to total fish oil. The EPA and DHA content (the only part that matters) is buried on the back.

This isn't an accident. It's how the industry systematically misleads consumers.

Real-world example: A plaintiff sued Whole Foods over their "Omega-3s EPA & DHA 1000mg Per Serving" front label. The back panel revealed the product contained 1000mg fish oil but only 300mg of omega-3s. The court found nothing misleading about this. Technically accurate. But consumers don't read labels that way.

The Capsule Count Problem

Fish oil capsules typically contain only 10-15% of the amount of omega-3s used in successful clinical trials.

To reach the 2g EPA+DHA dose used in anti-inflammatory studies, you'd need to take 6-7 capsules of a typical 300mg product.

To reach the 4g dose used in REDUCE-IT, you'd need 12-14 capsules of most retail fish oil supplements.

One analysis found that to get the omega-3 dose from a competitor's best-selling capsule, consumers would need to take 28 capsules per day. That would cost more than prescription omega-3s and deliver 220 unnecessary calories from neutral fat.

Brands formulate to a price point, not a clinical dose. They make vague structure/function claims ("supports heart health") that can't be substantiated at the doses provided. Consumers take 1-2 capsules daily, thinking they're getting cardiovascular or cognitive benefits, when they're actually getting 10-20% of the effective dose.

The Omega-3 Index: Measuring What Actually Matters

The Omega-3 Index (O3I) is the EPA+DHA content of red blood cells expressed as a percentage of total fatty acids. It was first proposed by Harris and von Schacky in 2004 as a risk factor for cardiovascular death.

Clinical target: 8% Omega-3 Index for cardioprotective effects.

Sudden cardiac death prevention: EPA+DHA blood level >5%.

Current reality: Four out of five supplement users have low omega-3 levels.

Translation: most people taking omega-3 supplements aren't actually achieving therapeutic tissue levels. They're underdosing by so much that their red blood cell membranes don't meaningfully change composition.

To raise Omega-3 Index to 8%, you need >1,000mg EPA+DHA daily for at least 12 weeks, and that's a maintenance dose. Most retail products deliver 300mg.

The Omega-3 Index isn't just for cardiovascular assessment anymore. It's now used to study cognitive function, atrial fibrillation risk, red blood cell structural integrity, and brain aging. Lower RBC omega-3 levels are associated with accelerated brain aging in imaging studies. Higher levels correlate with better outcomes across a remarkably large number of health conditions.

Omega-3 fatty acids are polyunsaturated. Multiple carbon-carbon double bonds make them structurally unstable. They oxidize easily when exposed to oxygen, light, or heat. Even oil stored in the dark at 4°C can oxidize unacceptably within a month.

Oxidized fish oil isn't just ineffective. It's potentially harmful. Lipid peroxides and secondary oxidation products (aldehydes) contribute to oxidative stress rather than resolving it.

TOTOX: The Gold Standard

TOTOX (Total Oxidation Value) combines primary oxidation products (peroxides) and secondary oxidation products (aldehydes) into a single number.

Formula: TOTOX = 2 × Peroxide Value (PV) + Anisidine Value (AV)

Quality standards:

• Excellent:: TOTOX <15
• Acceptable:: TOTOX ≤26 (IFOS 5-star requirement: PV ≤5 meq/kg, AV ≤20, TOTOX ≤26)
• Rancid:: TOTOX >26

Independent testing from 2023-2024 revealed that over half of commercial fish oil products exceed the 26 TOTOX limit. They're selling you rancid oil.

Most brands don't test TOTOX at all. They don't publish Certificates of Analysis. There's no regulatory requirement to disclose oxidation status. Consumers have no way to know whether the product they're buying is fresh or rancid.

IFOS (International Fish Oil Standards) operates a lot-by-lot testing program with all results accessible online for independent verification. But IFOS certification is voluntary and costs money, so most brands skip it.

Label Accuracy: Another Crisis

Even when brands list EPA and DHA content, you can't trust the numbers. One study testing commercial supplements found that the percentage of stated label amount for EPA and DHA ranged from 66% to 184%.

Only 21% of supplements had at least 100% of stated label amount of EPA.

Only 25% of supplements had at least 100% of stated amount of DHA.

You can't even trust the back label. The heterogeneity in actual EPA+DHA content leads to massive variability in safety and efficacy between products claiming similar doses.

Heavy Metals: Generally Controlled

The good news: heavy metal contamination in quality fish oil supplements is generally well-controlled. ConsumerLab.com testing found no detectable mercury in tested fish oil supplements, and most had only trace levels of PCBs.

Reputable manufacturers use molecular distillation or other purification methods to remove contaminants like mercury, lead, cadmium, and arsenic that can accumulate in fish tissues. The risk exists if you're eating whole fish (especially large predatory species), but properly purified fish oil supplements are safe.

The bad news: oxidation is a much bigger problem, and almost nobody is testing for it.

Stabilization: Tocopherols Help But Don't Prevent

Added tocopherols (vitamin E) inhibit free radical oxidation by reacting with peroxyl radicals to stop chain propagation. They also decrease formation of aldehydes (secondary oxidation products). They're the most important antioxidant used in omega-3 oils.

But they reduce oxidation, they don't prevent it. Even with tocopherol stabilization, you need proper storage (cool, dark, sealed), short time from manufacture to consumption, and ideally enteric coating to protect the oil from stomach acid exposure.

Krill oil has a natural advantage here: endogenous astaxanthin provides antioxidant protection as part of the whole-food matrix.

Specify TOTOX ≤15, require third-party testing (IFOS certification), include tocopherol stabilization, and provide Certificates of Analysis for transparency. Most brands won't do this because it costs money and might reveal quality problems. That's your competitive advantage.

Enteric Coating

Enteric coating resists stomach acid and dissolves in the small intestine, bypassing the stomach entirely. A study in Alimentary Pharmacology & Therapeutics found enteric-coated fish oil supplements reduced fishy burping by 65% compared to standard softgels in participants with previous burping issues.

Importantly, enteric coating has no significant influence on bioavailability of EPA and DHA. Uptake from enteric-coated capsules is not affected compared to uncoated capsules. It effectively reduces side effects without compromising absorption.

The mechanism for reflux: fish oil can stimulate relaxation of the lower esophageal sphincter, allowing acid to drift upward and causing heartburn. Enteric coating bypasses this mechanism entirely.

Softgel vs. Liquid

Liquid fish oil gets through the gut rapidly, unobstructed by a gelatin layer. Certain types of liquid medications can be 30-37% more bioavailable than capsule equivalents in some contexts. However, one study of a micellar formulation showed blood concentrations of total n-3 fatty acids up to 11 times higher than standard softgels. Formulation type can outweigh the liquid vs. capsule distinction. There's no significant difference in nutritional value between variants when properly formulated.

For convenience, taste, and clean label, capsules (softgels) often win. They're easier to swallow for many users, eliminate the need to measure doses or handle oil, and are more convenient for daily use and on-the-go routines.

For degradation and stability, softgel capsules protect oil from oxygen and light, reducing oxidation risk. They help maintain freshness longer than liquid fish oil once the bottle is opened. Fish oil liquids are more prone to oxidation and often benefit from refrigeration after opening to extend freshness.

Small Pelagic Fish: The Primary Sources

Most fish oil comes from small pelagic fish low on the food chain: anchovies, sardines, mackerel, menhaden, and sprat. These species contain roughly 30% omega-3 oil content.

The Peruvian anchoveta (anchovy) fishery is the largest single source of fish oil worldwide, with annual catches ranging from 3-7 million tonnes. This fishery alone strongly influences global oil supply and pricing.

Omega-3 content by species (per 100g):

• Anchovies:: 2,053mg EPA+DHA
• Sardines:: 982mg EPA+DHA
• Atlantic mackerel:: 1,500-2,500mg EPA+DHA

Think about that. One serving of anchovies contains more omega-3s than seven retail capsules. The natural source is vastly richer than what ends up in most supplements.

Sardines are more likely to be sustainably caught, making them a safe choice for pregnant and nursing women concerned about both omega-3 intake and environmental impact.

Cod Liver Oil: Not a Substitute

Cod liver oil is not the same as fish oil. It contains roughly 1/3 to 1/2 less EPA and DHA than fish oil because it's extracted from liver tissue rather than whole fish body.

More importantly, cod liver oil contains added vitamins A and D. One tablespoon contains 13,600 IU vitamin A and 34 mcg vitamin D. Because these are fat-soluble vitamins that can build up in the body, toxicity is a real concern. Vitamin A toxicity can lead to liver damage and vision harm. Vitamin D toxicity can cause hypercalcemia (elevated calcium in the blood).

For this reason, cod liver oil should not be taken in doses above 2,000mg due to vitamin A content. Most health organizations, including the NHS, recommend choosing fish oil over cod liver oil. It's likely best to take only fish oil or cod liver oil, but not both together.

Sustainability Certifications

The Marine Stewardship Council (MSC) published an updated Fisheries Standard (version 3.1) in 2024. The number of fish oil supplements in the U.S. featuring the MSC-certified label grew 44% in the past five years. Many fisheries from which marine oils are sourced have been certified or are currently pursuing MSC certification.

Friend of the Sea (FOS) is a globally recognized non-governmental organization established in 2008 with a mission to protect marine ecosystems by promoting sustainable and ethical practices. FOS certification mandates that omega-3 oils originate from fisheries adhering to strict measures to reduce environmental footprint. It includes strict traceability measures from catch to capsule. Every step of the supply chain is monitored to ensure supplements can be traced back to sustainable sources.

If you were designing an omega-3 supplement based on clinical evidence rather than cost optimization, here's what it would look like:

Molecular form: Re-esterified triglyceride (rTG) or high-quality natural TG from small pelagic fish. Concentration: 60-90% EPA+DHA.

EPA:DHA ratio: Matched to clinical indication.

• Cardiovascular/inflammation: 2:1 EPA:DHA or higher (consider EPA-only for high-risk populations)
• Cognitive/prenatal: 1:2 DHA:EPA or higher
• General wellness: 3:2 balanced

Dose per serving: 2-4 capsules delivering 1,500-4,000mg EPA+DHA depending on indication. Not one 300mg capsule.

Quality specifications:

• TOTOX ≤15 (ideally single digits)
• IFOS 5-star certification or equivalent third-party testing
• Certificate of Analysis published for each batch
• Heavy metal testing for mercury, lead, PCBs, arsenic
• Tocopherol stabilization

Delivery format: Enteric-coated softgels to reduce fishy burps and improve compliance. Studies show enteric coating reduces eructation by 65% without affecting bioavailability.

Sourcing: Sustainably harvested small pelagic species (anchovies, sardines, mackerel) with MSC or Friend of the Sea certification. Alternatively, algal oil for vegan positioning.

Claims: Specific, defensible, tied to clinical evidence at the dose provided. Not vague "supports heart health" but "provides 2g EPA+DHA daily, the dose shown in VITAL trial to reduce heart attack risk by 28%."

That's what formulation science looks like. It's not what you'll find in 95% of retail products.

The omega-3 market is broken because brands optimize for the wrong variables.

They optimize for cost per capsule instead of cost per clinically effective dose.

They optimize for front label claims instead of back panel reality.

They optimize for shelf appeal instead of evidence-based formulation.

The result: a race to the bottom where everyone sells underdosed, low-quality fish oil in 1000mg capsules with vague health claims.

The Problems Ceuvita Solves